Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas.
Rebecca VW, Xiao M, Kossenkov A, Godok T, Brown GS, Fingerman D, Alicea GM, Wei M, Ji H, Bravo J, Chen Y, Fane ME, Villanueva J, Nathanson K, Liu Q, Gopal YNV, Davies MA, Herlyn M.
Rebecca VW, et al. Among authors: davies ma.
bioRxiv [Preprint]. 2023 Jan 21:2023.01.20.524923. doi: 10.1101/2023.01.20.524923.
bioRxiv. 2023.
PMID: 36711814
Free PMC article.
Preprint.